PRESS RELEASES
Press Release
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
Press Release
Altasciences Appoints New General Manager, Clinical Operations
James Brazeal has joined Altasciences' as General Manager, Clinical Operations, of our Kansas City facility. Read more about James here.
Press Release
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. The impressive 8,000-square-foot space features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
Press Release
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray, GCPQ, under the trade name, AnQlar. Click to read more.
Press Release
Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)
Altasciences is pleased to have completed the successful Phase I trial of Ischemix’ novel drug candidate, CMX-2043, for the treatment of acute traumatic brain injury (TBI), at our Montréal clinical facility.